Axial Spondyloarthritis (axSpA) refers to a form of spondyloarthritis that primarily affects the sacroiliac joints and spine. It is characterized by chronic inflammatory back pain and stiffness. Biological disease-modifying anti-rheumatic drugs (bDMARDs) such as anti-TNF inhibitors, interleukin blockers are currently used in the treatment of axSpA. These drugs helps in reducing pain, inflammation and slowing progression of the disease. The global axial spondyloarthritis treatment market is driven by the increasing prevalence of ankylosing spondylitis and non-radiographic axial spondyloarthritis worldwide. It is estimated that nearly 2-5% of the world’s population is affected by axSpA. Moreover, growing awareness regarding early diagnosis and treatment of the disease is also fueling market growth.
The axial spondyloarthritis (axSpA) treatment market is estimated to be valued at USD 6.02 billion in 2024 and is expected to reach USD 10 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
Key Takeaways
Key players operating in the axial spondyloarthritis (axSpA) treatment market are Eli Lilly and Company, UCB, Biogen, Novartis, Janssen Pharmaceutical Companies and Abbott Laboratories.
Some major opportunities in the Axial Spondyloarthritis (axSpA) Treatment Market include rising approvals of new drugs like Eli Lilly's Olumiant for axSpA treatment. Eli Lilly recently received U.S FDA approval for Olumiant for adults with active ankylosing spondylitis. In addition, growing preference for biologics over traditional disease-modifying anti-rheumatic drugs(DMARDs) is another growth opportunity.
Globally, companies are expanding their operations in high growth regions. For instance, in 2021, AbbVie acquired Allergan and expanded its presence in emerging Asian markets. Similarly, UCB recently entered China market by gaining approval for its axSpA drug "Cimzia" in the country. Such global expansion strategies by key players are expected to drive market growth over the forecast period.
Market Drivers
Increasing research and development of novel therapeutics for axSpA treatment is a major market driver. Introduction of new mechanisms of action is exploring new treatment avenues. Moreover, rising collaboration between biopharma companies and research organizations for axSpA drug development is also fueling market growth.
Market Restrains High cost associated with biologic drugs remains a key challenge for extensive adoption. Biologics have been found to be quite expensive especially for patients in low-income countries. Moreover, lack of disease awareness in some regions also hampers early diagnosis and treatment, acting as a market restrain.
Segment Analysis
This market can be segmented based on drug class type which includes Nonsteroidal anti-inflammatory drugs (NSAIDs), Disease-modifying antirheumatic drugs (DMARDs) and Biologics. The biologics sub-segment currently dominates the market as these drugs are specifically targeted treatment which inhibits certain proteins responsible for inflammation. Biologics like tumor necrosis factor (TNF) inhibitors are highly effective in reducing symptoms and slowing progression of the disease.
Global Analysis
North America region holds a significant share in the axSpA treatment market due to developed healthcare infrastructure and availability of advanced treatment options. However, Asia Pacific region is expected to witness highest growth rate owing to increasing patient awareness, rising healthcare expenditure and growing demand for quality care. The large patient pool and improving access to healthcare facilities in emerging countries like China and India is likely to contribute towards the regional market growth during the forecast period.
Get This Report in Japanese Language: 軸性脊椎関節炎（axSpA）治療市場
Get This Report in Korean Language: 축성 척추관절염(axSpA) 치료 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
Non-radiographic axial spondyloarthritis market is a type of inflammatory arthritis, a hetrogenous group of autoimmune disorders that causes pain in lower back.
The non-radiographic means that the symptoms or inflammation will not visible on x-ray (radiograph) but can show on MRI (magnetic resonance imaging) scan however it can negative too and axial spondyloarthritis means arthritis affect mainly on the spine.
The patients with non- radiographic axial spondyloarthritis experience the severe back pain.According to the statistics puplished in the UCB S.A., an estimated adult population of non-radiographic axial spondyloarthritis is up to 0.5% to 1.4%.
Growing incidence of non-radiographic axial spondyloarthritis, accelerating demand of novel therapies and treatment are the key drivers for market growthThis Non-Radiographic Axial Spondyloarthritis Therapeutics Market research report intensely analyses the potential of the market with respect to current scenario and the future prospects by considering several industry aspects of Cardinal Health industry.
The report also recognizes and analyses the rising trends along with major drivers, challenges and opportunities in the market.
This Non-Radiographic Axial Spondyloarthritis Therapeutics Market report provides major statistics on the market status of global and regional manufacturers and is a helpful source of assistance and direction for companies and individuals interested in Healthcare industry.
